AHFS June 2024 Update

This update contains 6 new monographs and 44 revised monographs.

New monographs: Atidarsagene Autotemcel; Iloprost (Frostbite); Macitentan and Tadalafil; Pemivibart; Resmetirom; Tislelizumab-jsgr.

Revised monographs: Abatacept; Alemtuzumab (Antineoplastic); Alemtuzumab (Multiple Sclerosis); Alprostadil; Amantadine Hydrochloride (Antiparkinson); Amantadine Hydrochloride (Antiviral); Amiodarone Hydrochloride; Apalutamide; Asciminib Hydrochloride; Binimetinib; Cantharidin; Cisatracurium Besylate; Coagulation Factor IX (recombinant), GlycoPEGylated; Copanlisib Hydrochloride; Dalfampridine; Darolutamide; Darunavir; Dimethyl Fumarate; Diroximel Fumarate; Dostarlimab-gxly; Efgartigimod Alfa; Eflapegrastim-xnst; Emicizumab-kxwh; Erenumab-aooe; Everolimus; fentaNYL, fentaNYL Citrate; Finasteride (BPH); Finasteride (Hair Growth); Fremanezumab-vfrm; Galcanezumab-gnlm; Iloprost; Lopinavir and Ritonavir; Luspatercept-aamt; Nirmatrelvir and Ritonavir; Olaparib; Omaveloxolone; Pegcetacoplan (Geographic Atrophy); Rucaparib Camsylate; Selumetinib Sulfate; Sodium Oxybate; Somatropin; Teplizumab-mzwv; Tretinoin; Ublituximab-xiiy.